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Abstract
Background: By the end of 2011 Global Fund investments will be supporting 3.5 million people on antiretroviral therapy
(ART) in 104 low- and middle-income countries. We estimated the cost and health impact of continuing treatment for these
patients through 2020.
Methods and Findings: Survival on first-line and second-line ART regimens is estimated based on annual retention rates
reported by national AIDS programs. Costs per patient-year were calculated from country-reported ARV procurement prices,
and expenditures on laboratory tests, health care utilization and end-of-life care from in-depth costing studies. Of the 3.5
million ART patients in 2011, 2.3 million will still need treatment in 2020. The annual cost of maintaining ART falls from $1.9
billion in 2011 to $1.7 billion in 2020, as a result of a declining number of surviving patients partially offset by increasing
costs as more patients migrate to second-line therapy. The Global Fund is expected to continue being a major contributor
to meeting this financial need, alongside other international funders and domestic resources. Costs would be $150 million
less in 2020 with an annual 5% decline in first-line ARV prices and $150–370 million less with a 5%–12% annual decline in
second-line prices, but $200 million higher in 2020 with phase out of stavudine (d4T), or $200 million higher with increased
migration to second-line regimens expected if all countries routinely adopted viral load monitoring. Deaths postponed by
ART correspond to 830,000 life-years saved in 2011, increasing to around 2.3 million life-years every year between 2015 and
2020.
Conclusions: Annual patient-level direct costs of supporting a patient cohort remain fairly stable over 2011–2020, if current
antiretroviral prices and delivery costs are maintained. Second-line antiretroviral prices are a major cost driver, underscoring
the importance of investing in treatment quality to improve retention on first-line regimens.
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Introduction
As of the end of 2009, over 5 million people were receiving
antiretroviral treatment (ART) globally [1]; 2.5 million people
through programs co-financed by the Global Fund to Fight AIDS,
Tuberculosis and Malaria (Global Fund) [3]. Seventy-seven
percent of Global Fund-supported patients were in sub-Saharan
Africa, 15% in Asia, 3% in Latin America/Carribean, 3% in
Eastern Europe & Central Asia each, and1% in the Middle East.
By 2011, Global Fund-supported programs in 104 low- and
middle-income countries will aim to scale-up to have 3.5 million
people on ART according to service delivery targets of existing
grants and approved proposals [4] — a remarkable success, given
that in 2003 only 400,000 people with HIV in low- and middle-
income countries were receiving ART [2].
Increased international financing has enabled the rapid growth
in the number of people receiving ART, though including all those
who do not currently have access to treatment will require US$ 7
billion annually, as a minimum estimate based on the WHO’s
2006 treatment eligibility criteria [5]. While studies have projected
increased financing needs to treat all those who need it [6], none
have estimated the level of financing required to support the
patients currently receiving ART, which could be seen as a
minimum to funding requirements.
We use new data on Global Fund financing of ART programs to
estimate the future funding required to enable the cohort of 3.5
million persons expected to be receiving ART in Global Fund-
supported programs as of 2011 to continue receiving treatment
through 2020. We also compute the health impact of continued
provision of ART for this cohort, in terms of deaths averted/
postponed and life-years saved, and explore key determinants of cost.
Methods
We estimate the long-term costs and impact of Global Fund
support by following the cohort of patients on treatment in 2011.
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programs over next years are not considered in the current
analysis, for simplicity and in order to establish a minimum
commitment. We estimate the future cost and health impact by
projecting the number of patients that will still be alive and
receiving treatment in future years by subtracting those that die of
AIDS or non-AIDS causes. Although some patients may stop
therapy voluntarily that does not reduce the obligation to continue
them on treatment if they desire it.
We have used as a starting point the number of patients on
ART with Global Fund support in 2011. While the actual grant
delivery results for 2011 will not be available until early 2012, the
funding committed for ART treatment is already in place, and
supported programs have each set their target for the number of
people to receive treatment through ongoing grants and approved
grant proposals for next calendar years.
Patients are assumed to survive according to recent, interna-
tionally agreed best estimates of current rates of survival, as
discussed below. Patients may also fail first line treatment and
require more expensive second line. Although many patients live
in countries where the provision of second line is inadequate we
assume that all patients get second line when they need it, for the
purpose of estimating the funds required to provide necessary
treatment.
Impact is measured in terms of deaths averted and life-years
gained, as detailed below, comparing the actual patient cohort
with a counterfactual scenario in which essentially all those
patients on treatment in 2011 would die within a few years if they
could not longer access treatment.
Cohort survival on first-line and second-line treatment
For the 2011 cohort of 3.5 million patients, ART need in future
years is estimated based on the retention and survival of those
patients in each subsequent year. According to reports submitted
to the World Health Organization (WHO) by 38 national AIDS
programs in low- and middle-income countries in 2008, the
proportion of patients (adults and children) remaining on
treatment – i.e. not dying and not lost to follow-up – averaged
80% at 12 months after treatment initiation, and 75% after 24
months, 74% after 36 months and 73% after 48 months [2]. These
figures vary by region with the best 48-month retention rates
achieved in Latin America and the Caribbean (74%), followed by
North Africa and the Middle East (78%). Lower retention rates are
achieved in Europe and Central Asia (67%), sub-Saharan Africa
(67%) and East, South and South-east Asia (55%). Based on an
unweighted average across the regional survival/retention data,
we assume an annual survival of 79.5% for the first year, and 96%
survival for each subsequent year, for all countries. For example,
in 2011 alone there are 790,000 new patients who initiated
treatment, 79.5% of whom will survive into 2012, while 96% of
continuing patients will survive to 2012. After 2012 all patients
continue with a 96% survival rate.
For the start year of projections, 2009, we used the WHO 2008
survey for 38 National AIDS Programs to determine country-
specific proportions of patients on second-line regimens. For
countries not participating in this survey, we applied regional
weighted average proportions. Across all Global Fund-supported
countries, the weighted average proportion was 2.5% of patients
on second-line regimens. For subsequent years, we calculated the
proportion of patients on second-line regimens using regional
migration rates with an average of 1.9% of patients who survived
on first-line regimens switching to second-line regimens each year
[7].
Health impact
We estimated the health benefits of Global Fund-supported
ART by comparing survival of patients initiating and continuing
treatment, with a counterfactual cohort for which continued
treatment was not available from 2011 onwards.
To calculate the health impact of continued ART, we assumed
that all HIV-infected people starting ART have advanced disease
and meet standard ART eligibility criteria, according to the
WHO’s 2006 Treatment Guidelines which propose ART for HIV-
infected people with clinical stage III or IV disease, and/or CD4
below 200/mL [8]. This is in line with program data reported by
low- and middle-income countries to the 2008 WHO survey, in
which CD4 counts at treatment initiation are often well below
200/mL, for example a median of 67/mL among 13 African
countries [2]. Survival on ART is calculated as specified above.
For the counterfactual scenario that these patients in need would
not continue to receive ART, we calculated mortality based on
data on people in acute need of treatment but never on treatment.
Based on the time from infection to AIDS deaths as analyzed by
the ALPHA network, a collaboration of cohort studies in Africa
[9,10], the cumulative proportion of a cohort currently on ART
that would die if ART were stopped would be 18% after 1 year,
46% after two years, 64% after three years, 76% after 4 years,
84% after 5 years, and 97% after 5 years – with median survival
being 3 years. Using these cumulative mortality rates in a Weibull
survival curve [12], we calculated the number of people that would
still be alive over subsequent calendar years with and without
ART, to estimate numbers of deaths averted and life-years saved
in each calendar year. Although most patients on treatment in
2011 started treatment in earlier years and thus may have
improved immune systems, we assumed that if treatment were
stopped abruptly they would have survival patterns similar to those
who became eligible for treatment but never received it, so survive
for a median slightly more than 2 years after the cessation of
treatment.
Cost per patient-year of ART
Estimates of cost per patient-year of ART are shown in Table 1.
These costs represent overall, recurrent patient-level direct costs,
to which the Global Fund contributes alongside other partners and
domestic resources.
Prices for both first-line and second-line ARVs vary substan-
tially by country but have declined over recent years. Based on
country-reported procurements reported through the Global
Fund’s Price and Quality Reporting system and WHO’s Global
Price Reporting Mechanism, median prices across Global Fund-
supported countries were $204 for first-line drugs and $1238 for
second-line drugs as of 2009 [4].
In most programs ART patients are monitored with laboratory
tests for CD4 counts, blood chemistry and hematology. Some
programs also include viral load monitoring. Treatment protocols
usually specify monitoring every three to six months. Our review
of 15 published reports from low- and middle-income countries on
the costs of laboratory tests found a median annual cost of $180 for
monitoring each patient receiving ART (Table S1) [13–27].
Service delivery costs for ART care (personnel, supplies,
facilities, etc.) also vary by country; depending on the frequency
of visits, the type and level of health care facilities and clinical staff
used for monitoring patients and local health worker salaries. Our
review of studies from eight countries which have reported on the
annual number of in-patient days and out-patient visits estimated a
median of 9.5 out-patient visits and 1.6 in-patient days per ART
patient per year (Table S2) [7–9,11,12,28–30]. Country-specific
estimates of the cost per in-patient day in a primary-level hospital
Impact of Global Fund ART Support
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CHOICE database [31]. We combined global average frequencies
of in-patient days and out-patient visits with country-specific costs
from WHO-CHOICE to estimate a median annual cost of $138
per patient receiving ART.
Using review results we calculated non-ART care requirements,
once HIV patients fail ART, at 5.5 out-patient visits, 9.7 in-patient
days and $49 in non-ARV drug costs per patient-year. Based on
WHO-CHOICE country estimates of the cost of hospital days and
outpatient visits in each country [32], this corresponds to a median
health care cost of US$ 320 per year. For patients dying on ART
We added end-of-life care costs of US$ 160 per patient, incurred
during the last half year before death from HIV/AIDS.
All costs are expressed in 2008 US dollars.
Sensitivity analysis: ARV price, cost and regimen changes
Cost estimates were repeated in sensitivity analysis that varied,
univariately, the future prices of first-line and second-line ARVs,
the mix of ARV regimens used and the rate of migration from
first-line to second-line ARV regimens. (In our model, we assumed
these changes to not affect health impact.)
Results
Survival and cost
Of the 3.5 million people receiving ART with Global Fund
support in 2011, we estimate that 2.3 million will still be alive and
receiving treatment in 2020. (Figure 1) The proportion of these
patients receiving second-line regimens will rise from 2.5% in 2009
to 24% by 2020. The full annual cost of supporting these patients
will decline by 10% from about US$ 1.9 billion in 2011 to US$ 1.7
billion in 2020. Although the number of people remaining on
treatment will decline by 35% by 2020, the larger proportion on
more expensive second-line treatment means annual drug costs
will decline by only 17%. By 2020, the 24% of patients on second-
line regimens will account for 50% of the total program cost
(Figure 2).
Health impact
The health impact of continuing the 2011 cohort of patients on
ART will be quite large since all those receiving ART today would
die by 2020 if they stopped ART. The largest number of deaths
(860,000) is averted in 2012, the year after the 2011 cohort reaches
its full size (Figure 1). The annual number of deaths averted then
falls gradually over subsequent years (Figure 3). From 2018
onwards, no additional deaths are averted, since most of those
people currently on ART would be dead by then if they stopped
treatment in 2010. Continuation of the 2011 cohort of patients on
ART will postpone some deaths until 2018–2020, leading to more
deaths in those years with continued ART than without.
The averted deaths correspond to 860,000 life-years saved in
2012, increasing to 2.3 million annual life-years saved by 2017
(Figure 4). Cumulatively over 2011–2020, continued ART is
estimated to save 17.7 million life-years.
Sensitivity analysis: ARV price, cost and regimen changes
The future investment required to support those currently
receiving ART will be influenced by a number of factors including
changes in ARV prices, the distribution of patients over ARV
regimens of differing prices, and patient laboratory monitoring
practices. The median prices of the most commonly used first-line
ARVs declined by an average 12% per year from 2006 to 2009
[3]. This pace of decline is not likely to continue for first-line drugs.
In 2010, the Global Fund committed to achieve a median 5%
annual price decline for commonly used first-line ARVs across the
ART programs it supports, as a corporate Key Performance
Indicator [33]. For the 2011 cohort, a 5% annual decline after
2010 would reduce the estimated cost in 2020 by $260 million or
by 15% compared to our baseline cost estimate for 2011 of $1.7
billion (Figure 5).
Considering the higher current prices there is more scope for
faster declines in second-line ARV prices in coming years [34]. An
annual reduction in second-line prices of 11% every year until
2015, with prices maintained at 2015 level thereafter, in line with
what has been achieved over 2006–2009 and with the Global
Fund Key Performance Indicator for first-line ARVs, would
diminish estimated costs in 2020 by $560 million or by 34%.
The average per-patient cost of first-line regimens may rise in
the future as countries implement the revised 2009–10 WHO
ART guidelines [34] to phase out the use of stavudine (d4T), the
least expensive first-line drug. If all patients currently on d4T-
containing regimens were switched to other first-line regimens in
proportion to 2008 usage patterns [1], the median price of first-
line ARVs would rise from $204 in 2009 to $254 in 2015 per
patient per year. The financing needs in 2020 would consequently
increase by at least $120 million (7%) in total. (The increase could
Table 1. Assumed costs of ART delivery.
Cost component US $ Source
First-line ARVs: 1 patient-year 204
# Global Fund Price & Quality Reporting system and WHO Global Price Reporting mechanism
[4,5], for the patient-weighted mix of the 6 first-line or second-line ARV regimens that were
most commonly used in low- and middle-income countries over 2006–8 [1].
Second-line ARVs: 1 patient-year 1,238
#
Laboratory testing: 1 patient-year 180 Comprehensive costing studies (see Supporting Online Material, Table S1)
Treatment delivery: 1 patient-year 138 WHO-CHOICE country estimates [6] (see Supporting Online Material, Table S2)
End-of-life treatment of opportunistic infections: per
patient lifetime
160 During a patient’s last year on ARV therapy only. Based on WHO-CHOICE [6] and literature
review of non-ARV therapy costs of HIV care. [See supporting on-line material]
Total first-line ART (1 patient-year) 487
#
Total second-line ART (1 patient-year) 1,521
#
#ARV and ART cost assumptions are based on country-specific estimates of ARV and service delivery cost and a fixed cost for laboratory and end-of-life treatment of
opportunistic infections. The shown average ‘Total’ is weighted across Global Fund-supported AIDS programs according to their number of patients at end-2009. The
shown weighted average costs of the individual components do not add up to the weighted average total cost per patient, because of considerable variation among
countries in the cost of ARVs and treatment delivery.
doi:10.1371/journal.pone.0021048.t001
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to better adherence and survival on ART.)
Countries that use routine viral load monitoring have higher
migration to second-line regimens, around 6%, than those that do
not routinely monitor viral load (2.6% in sub-Saharan Africa and
Latin America and the Caribbean, and 1.1% in Asia). If all Global
Fund-supported countries had 6% annual migration to second-line
regimens, then financing needs in 2020 would increase by $560
million, a 33% increase.
Discussion
The number of people receiving ART in low- and middle-
income countries has expanded rapidly in recent years. Much
work has focused appropriately on what is required to continue
this scale-up to reach all those in need of treatment. This study
examines a previously unexplored aspect of treatment, the
financing required to continue supporting patients receiving ART.
Investments by the Global Fund together with other partners
have enabled and catalyzed a rapid expansion of HIV programs in
low- and middle-income countries that is reducing mortality and
new infections [36,37]. As of the end of 2009, Global Fund grants
co-supported, fully or partially, around half of all patients receiving
ART globally. For the 3.5 million patients receiving ART as of
2011, at current cost levels the annual resource need ranges from
US$ 1.9 billion in 2011 to US$ 1.7 billion in 2020. The Global
Fund does not support all of these costs; the USA President’s
Emergency Plan for AIDS Relief (PEPFAR), other donors,
national governments and other domestic resources also provide
partial support for the patients benefiting from Global Fund
investments. Based on expenditure reporting from Global Fund
recipient HIV/AIDS programs, across countries with Global
Fund-supported ART the average annual expenditure from
Global Fund grants per person-year of ART was estimated at
about a quarter of the full program-level ART delivery costs
estimated in this paper [4]. This is roughly consistent with the
Global Fund’s share in overall international AIDS control funding,
which in 2008 equalled 19% [38].
The costs of treatment in this analysis vary only by first and
second line treatment. In reality costs may be different for different
types of patients, pregnant women, children, TB patients. We have
used an average per patient cost, which implicitly assumes that the
distribution of patients by type will not change.
Sensitivity analyses showed that program costs are sensitive to
ARV prices and regimens used, in particular for second-line ARV
regimens. A balanced use of lower-cost generic ARVs and more
Figure 1. HIV/AIDS patients on ART in Global Fund supported programs according to end-2010 grant results and 2011 grant
service delivery targets of ongoing grants and approved grant proposals (up to and including Round 10), and expected retention
on first-line (FL) and second-line (SL) ARV regimens over future years.
doi:10.1371/journal.pone.0021048.g001
Figure 2. Cost of continued ART for Global Fund-supported patients as of 2011: first-line versus second-line regimens.
doi:10.1371/journal.pone.0021048.g002
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treatment quality to retain patients on first-line regimens will be
critically important to manage future costs. Equally, considerable
variations in the protocols and frequencies of laboratory testing
and associated cost point to opportunities for efficiency gains in
patient monitoring. Recent studies in resource-constrained settings
suggest that CD4-based patient monitoring is generally cost-
effective compared to clinical monitoring alone, but that viral load
(HIV RNA) monitoring is not always cost-effective [45–49]. While
lack of laboratory capacity should not impede countries to roll-out
first-line ART, there is a need to develop affordable, point-of-care
viral load and CD4 assays that can supplement clinical monitoring
and ensure timely detection of treatment failure and regimen
switches [50].
To further refine this type of assessment, we will need
progressively better information on country-level variation and
determinants of cost of ART delivery [39]. Recently established
routine tracking of national program budgets and expenditures
can contribute to fill this current data gap [40], and inform the
effects of ARV drug price declines, changing treatment eligibility
criteria and regimen mixes, and the proportion of patients on first-
and second-line ART [2,9]. As of now, a paucity of country-level
expenditure data on especially non-ARV components limits our
understanding of current and future ART delivery cost in different
settings. Routine expenditure data collection by national AIDS
programs will also assist in optimizing value for money, an
important determinant of future national and international (donor)
commitments to ongoing ART scale-up [4,6,51–54].
Also, program achievements in terms of patient retention and
survival, on first-line and second-line regimens, deserves improved
monitoring and assessment. In-depth studies and evaluations in
countries with relatively advanced patient tracking systems suggest
that routine national program records may overestimate actual
retention and survival in several high-HIV countries, given
elevated mortality among patients lost-to-follow-up, and (passive)
over-counting of retention time among patients who dropped out
from recent clinic or pharmacy appointments. On the other hand,
patients transferring between facilities may be over counted as new
initiations and undercounted in retention [55–58]. In high-HIV
countries with substantive ART coverage, triangulation of
program and clinical data with population-level mortality trends
from vital registration, surveys and censuses would provide the
ultimate reassurance on population-level health impact [59–60].
Weestimatecontinuedinvestmentneedsforacohortof3.5million
people receiving ARVs. The global need for treatment and financing
of HIV is far larger than this number. The 2010 revised WHO HIV
Treatment Guidelines [35] raisethe estimate ofthe numberof people
in need of treatment by about 50% [41]. UNAIDS estimates suggest
funding for ART would have to expand to US$ 7 billion annually by
2015 in order to achieve 80% coverage of those most acutely in need
(with CD4 counts under 200 cells/mL), and would further increase by
50% to achieve 80% coverage under the expanded treatment
eligibility criteria (covering all those with CD4 counts under 350
cells/mL) [41]. Globally the number of patients on ART has been
increasing at almost one million patients per year between 2006 and
2008. If that rate of scale up were to continue through 2020 and the
Global Fund continued to support about 62% of ART patients as it
did in 2009 [3], then the number of patients needing Global Fund
support would increase to 9 million by 2020. This would correspond
to an annual co-investment need by the Global Fund of $5.2 billion—
assuming constant grant expenditures per patient supported and
continued proportionate co-investments from domestic sources,
PEPFAR and other donors. However, there is no guarantee that
scale-up in funding from domestic and other donor sources would
keep pace with the ongoing rate of new ART patient initiations. Thus
the Global Fund is likelyto remain an important source of support for
most countries. While some middle-income countries with strong
economic growth could assume greater responsibility for funding
their own programs, thus reducing the Global Fund investment
needs,this isunlikelyto be the case in low-incomecountrieswhere the
majority of Global Fund beneficiaries live [6].
While this study examined ART costs for existing patients
through the year 2020, investment needs continue beyond this
date, as by that year 2.3 million people (66% of the 2011 cohort)
will still be alive and in need of continuing treatment Support for
these patients will also include non-ART costs such as prevention
and treatment of opportunistic infections including tuberculosis
and malaria [61,62]. Costs considered did not include the above-
facility level costs such as human resources at drug distribution
centers, district/provincial/national program management, mon-
itoring and evaluation, health worker training in AIDS manage-
ment and health system strengthening in general. A recent
evaluation across 6 PEPFAR-supported African AIDS programs
estimated above-facility-level costs at 20% of overall costs [63].
In conclusion, the rapid expansion of ART in low- and middle-
income countries in recent years has produced dramatic declines in
mortality and represents an important success in our efforts to improve
Figure 3. Number of patients on ART and patients surviving if
ART were discontinued from 2011.
doi:10.1371/journal.pone.0021048.g003
Figure 4. Expected health impact: mortality and lives saved
from ART: Deaths averted and life-years saved.
doi:10.1371/journal.pone.0021048.g004
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investment from international donors such as the Global Fund, as well
as sustained contributions by the governments of supported country
programs.
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